A PHASE 3, TWO-PART, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA INJECTION IN ADULT PARTICIPANTS WITH COMPENSATED CIRRHOSIS (STAGE F4 FIBROSIS) DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (NEBULA-2)
- Registry ID
- 308623
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Last update
- 2026-07-22
Conditions
- METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH KNOWN OR SUSPECTED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-2)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH BIOPSY-CONFIRMED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED BOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-1)
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS
WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS (MASH)
- A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH
COMPENSATED CIRRHOSIS SECONDARY TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS
WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS
View on source registry